절제 가능한 HNSCC 환자의 신보강 및 보조 요법을 위한 화학요법과 펜풀리맙의 병용
절제 가능한 두경부 편평세포암종 환자의 신보강 및 보조 요법을 위한 화학요법과 Penpulimab의 병용에 대한 제2상 임상 연구
This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200011
- Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients voluntarily joined the study, signed the informed consent, and had good compliance;
- Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-1;
- Patients with untreated head and neck squamous cell carcinoma who were pathologically confirmed and determined to be suitable for surgical treatment were classified as stage III, IVa according to AJCC (8th Edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
- Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.
Exclusion Criteria:
- Patients who have previously used PD-1/PD-L1/CTLA-4 antibody therapy;
- Patients who require systemic treatment with corticosteroids (> 10mg daily prednisone equivalent) or other immunosuppressive drugs within 14 days prior to administration or during treatmentIn the absence of active autoimmune disease, inhaled or topical steroids and adrenocortical hormone at doses >10mg/ day equivalent to prednisone and adrenocortical hormone replacement at therapeutic doses not exceeding 10mg/ day prednisone are permitted;
- A history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Active or uncontrolled severe infection within 4 weeks prior to enrollment (CTCAE grade 2 infection);
- Abnormal function of major organs
- Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Penpulimab combined with cisplatin and albumin-paclitaxel neoadjuvant therapy
Penpulimab injection combined with cis-platinum and albumin-bound paclitaxel before surgery, 21 days as a treatment cycle. Adjuvant therapy was started within 6 weeks after surgery：Patients who achieved MPR after surgery were randomized 1:1 with standard adjuvant therapy(RT alone or combined with cisplatin) and Alternative adjuvant therapy(RT alone or combined with Penpulimab). Non-MPR patients receive standard adjuvant therapy |
Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle). Cisplatin :75mg/m2, D1, IV(21 days/cycle) albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Major pathological response（MPR）
기간: One year
|
Major pathologic response is based on the pathological examination on the post-operative specimens. |
One year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease-control Rate（DCR）
기간: Baseline up to 3 years.
|
The proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks). |
Baseline up to 3 years.
|
|
Adverse event rate
기간: Baseline up to 3 years.
|
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
Baseline up to 3 years.
|
|
Disease-free survival at 2 years(DFS at 2 years)
기간: Baseline up to 2 years.
|
The proportion of subjects disease-free survival at 2 years |
Baseline up to 2 years.
|
|
Overall Response Rate (ORR)
기간: Baseline up to 3 years.
|
The proportion of subjects who achieves a best overall response of CR or PR. |
Baseline up to 3 years.
|
|
Local recurrence-free survival at 2years(LRFS at 2 years)
기간: Baseline up to 2 years.
|
The proportion of subjects local recurrence-free survival at 2years |
Baseline up to 2 years.
|
|
distant metastasis-free survival at 2 years(DMFS at 2 years)
기간: Baseline up to 2 years.
|
The proportion of subjects distant metastasis-free survival at 2years |
Baseline up to 2 years.
|
|
OS at 2 years
기간: Baseline up to 2 years.
|
The overall survival time refers to the time from initiating inductive therapy to death due to any cause. |
Baseline up to 2 years.
|
|
pathologic complete response(pCR)
기간: One year
|
Pathological examination showed the presence of 0% active tumor in the tissue specimen |
One year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ALTER-HN001
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .